Signal
FDA lifts one of two clinical holds on intellia CRISPR TTR program
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-27 16:59 UTCUpdated 2026-01-27 18:12 UTC
rssx
intelliacrisprfdaclinical_holdtransthyretin_amyloidosissafety
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Regulators partially eased restrictions on Intellia’s CRISPR program in transthyretin amyloidosis after serious safety concerns prompted pauses in two late-stage studies. The update allows one Phase 3 study to resume while another trial remains on hold, with the company describing added safeguards in response to the reported death and liver event.
Entities
Intellia
Score total
1.31
Momentum 24h
3
Posts
3
Origins
2
Source types
2
Duplicate ratio
33%
Why now
- FDA updated trial status: one hold lifted, one still in place
- Update follows reported grade 4 liver event and subsequent patient death
- Company says it is instituting new safeguards after the pauses
Why it matters
- Partial hold lift lets a Phase 3 study restart after serious safety concerns
- A second trial remains paused, signaling ongoing regulatory scrutiny
- Safeguards may influence how late-stage CRISPR trials manage risk
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- FDA lifted one of two clinical holds on Intellia’s CRISPR therapy program in transthyretin amyloidosis, allowing a Phase 3 study to resume while another trial remains suspended.
- The holds followed a reported grade 4 liver event and a subsequent patient death in a sister study; Intellia said it is instituting new safeguards.
How sources frame it
- BioPharma Dive: neutral
- Fierce Biotech: neutral
Two trade outlets report the same regulatory update; details on the remaining hold are limited in the provided posts.
All evidence
All evidence
The FDA is freeing Intellia’s CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was repo...
Fierce Biotech (All) · fiercebiotech.com · 2026-01-27 18:00 UTC
FDA lifts hold on an Intellia CRISPR drug trial
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-27 16:59 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (All) (1)
- BioPharma Dive (Latest) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)